Gözde Kübra Yardimci, MD, began her one-year Vasculitis Clinical Research Consortium (VCRC)-Vasculitis Foundation (VF) Fellowship in July 2022 at Mount Sinai Hospital, University of Toronto, Ontario, Canada. Her main areas of interest at present are severe ischemic events in Takayasu arteritis and Behçet’s syndrome. Through her fellowship, Dr. Yardimci is…...
FDA Approves Otezla®for the Treatment of Oral Ulcers in Behcet’s Disease
Celgene Corporation announced on July 19 that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behcet’s disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only…...
